China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
 and Lead Plaintiff Deadline - January 5, 2017 - EconoTimes)
NEW YORK, Nov. 28, 2016 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed against Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) (NYSE:TEVA) and certain of its officers. This class action is on behalf of a class consisting of all persons who purchased Teva between February 10, 2015 and November 3, 2016, both dates inclusive (the "Class Period").
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Teva was involved in and/or had been involved in conduct that would result in an antitrust investigation by the U.S. Department of Justice and the State of Connecticut Office of the Attorney General; (2) the DOJ investigation and the misconduct may instigate U.S. prosecutors to file criminal charges against Teva for alleged price manipulation; (3) as a result, Teva lacked effective internal controls; and (4) consequently, Teva’s public statements were materially false and misleading at all relevant times.
No Class has yet been certified in the above action. To discuss this action, or for any questions, please visit the firm’s site: http://www.bgandg.com/teva or contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Teva, you have until January 5, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
